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service as the item being valued. We examined whether
DC CV questions lead to hypothetical bias for this good,
and we tested whether “definitely sure” hypothetical yes
responses, as identified in a follow-up question, corre-
spond to real yes responses. METHODS: 172 subjects
with asthma were recruited from 10 Kentucky commu-
nity pharmacies. Subjects received either a DC CV ques-
tion or were given the opportunity to actually purchase
the service. Three different prices were used: $15, $40,
and $80. RESULTS: In the hypothetical group 38% of
subjects stated they would purchase the good at the given
price, but only 12% of subjects in the real group pur-
chased the good (p  0.000). We cannot, however, reject
the null hypothesis that “definitely sure” hypothetical yes
responses correspond to real yes responses. CONCLU-
SIONS: The DC CV method overestimates WTP in the
HCS, but it may be possible to correct for this by sorting
out “definitely sure” yes responses.
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OBJECTIVE: The primary objective was to evaluate the
relationship between willingness to pay (WTP), quality of
life (QOL), and disease severity measures in asthma pa-
tients. The hypothesis studied was that asthma patients
with more severe disease, as measured objectively via
forced expiratory volume percent predicted (FEV1%),
are willing to pay more for a hypothetical cure from
asthma than those with less severe disease. METHODS:
One-hundred asthmatic patients were recruited from
community pharmacies in Kentucky for 30 minute face-
to-face interviews. Spirometry was used to assess ob-
jective disease severity while a multiple choice question
assessed subjective disease severity. The Short Form 36
(SF-36) and Asthma Technology of Patient Experience
(Asthma TyPE) measured QOL. WTP was obtained via a
dichotomous choice contingent valuation question. RE-
SULTS: WTP was significantly related to both objective
disease severity (p  0.02) and subjectively assessed dis-
ease severity (p  0.01). For objective disease severity the
mean monthly WTP was $90 for mild asthma, $131 for
moderate asthma and $331 for severe asthma; and for
subjective disease severity the mean monthly WTP was
$48 for mild asthma, $166 for moderate asthma and
$241 for severe asthma. A majority of the QOL measures
were correlated with WTP. CONCLUSIONS: The results
suggest that the WTP for a cure from asthma is related to
both objective and subjective disease severity.
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OBJECTIVES: Cilomilast is a potent and selective phos-
phodiesterase type 4 (PDE4) inhibitor currently under
development for the treatment of chronic obstructive pul-
monary disease (COPD) and asthma. METHODS: COPD-
related health care resource utilization including physi-
cian visits, emergency room visits, hospitalizations and
medication use were prospectively collected in a 6 month
randomized, double-blind, placebo controlled, parallel
group study of patients on cilomilast, 15 mg bid (n 
431) versus patients on placebo (n  216). Methods of
analysis included descriptive statistics, Kaplan-Meier esti-
mates and Poisson regression. RESULTS: In the year
prior to the study, COPD-related health care resource
utilization was comparable between patients eventually
randomized to cilomilast and those randomized to pla-
cebo; the majority of all patients had no or one emer-
gency room visit or hospitalziation. During the entire 24-
week study period, the cumulative incidence of health
care utilization was significantly lower in the cilomilast
group than the placebo group in terms of all utilization
(11.0% vs. 21.1%, p  0.004); including physician visits
(11.9% vs. 23.1%, p  0.002), emergency room visits
(0.6% vs. 4.5%, p  0.004) and hospitalization (0.5%
vs. 3.4%, p  0.021). The relative utilization rates per
patient-month of follow-up for each of the utilization
types were lower in the cilomilast group than in the pla-
cebo group. Treatment with cilomilast resulted in reduc-
tion of all utilization by 51% (C.I.: 31%, 65%), physi-
cian visits by 41% (C.I.: 15%, 59%). ER visits and
hospitalizations were also significantly reduced. CON-
CLUSIONS: In this study, cilomilast was associated with
significantly less COPD-related health care resource utili-
zation, including hospitalizations, emergency room visits
and physician visits than placebo.
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OBJECTIVES: Asthma is a common medical condition
that is increasing in prevalence. The purpose of this study
was to examine costs associated with treating asthma pa-
tients within a managed care organization (MCO).
METHODS: Data for this study were obtained from a
managed care organization located in the Western region
of the US. Patients were eligible for inclusion if they met
one of the following criteria: a diagnosis of asthma (ICD-
9 code of 493.xx); two or more prescriptions used to
control asthma (e.g., inhaled corticosteroid, leukotriene
